Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 35a: Olaparib Maintenance in BRCA-wt Ovarian Cancer
NCT05233982Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 60 months. Started Dec 2021; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05233982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233982.